To Get Full Access :

aBLA Filing Intelligence & Biosimilar Opportunity

Kisunla

Donanemab-Azbt
Antialzheimer
Intravenous Infusion

Kisunla is used to treat Alzheimer’s disease. It is an FDA-approved treatment for early symptomatic Alzheimer’s disease, including mild cognitive impairment and the mild dementia stage of the condition.

Approval Date
02-Jul-24
Data Exclusivity Expiry
02-Jul-28
Market Exclusivity Expiry
02-Jul-36
Commercial snapshot

Market performance & projections

Revenue ($M)
249
CAGR (%)
63.58%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
596
2027
953
2028
1,378
2029
1,783
2030
2,100
2031
2,422
2032
2,733
Molecule profile

Details & specifications

Molecule
Donanemab-Azbt
Innovator
ELI LILLY
Dosage Form
Intravenous Infusion
Strength
350 mg/20 mL
Therapeutic Category
Antialzheimer
Usage
To treat Alzheimer’s disease
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?